Glucophage Sr

Glucophage Sr is a prescription medication that contains the active ingredient metformin hydrochloride. It is supplied as an oral tablet (strength not specified) and is marketed in the European Union. As a biguanide antidiabetic drug, Glucophage Sr lowers hepatic glucose production and improves peripheral insulin sensitivity, and it is used in adults with type 2 diabetes mellitus as part of a comprehensive individualized clinical treatment plan.

Glucophage Sr is indicated for the management of type 2 diabetes mellitus in adults.

- As monotherapy when diet and exercise are insufficient. - In combination with other oral antidiabetic agents. - As adjunct to insulin therapy when additional glucose control is needed. - To improve glycemic control as part of a comprehensive diabetes management program. - When combined with lifestyle modifications to achieve target HbA1c levels. - As part of fixed‑dose combinations with other oral agents, if clinically appropriate.

Side effects reported with metformin-containing products vary in frequency and severity.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Mild headache. - Decreased appetite.

Serious: - Lactic acidosis, a rare but potentially fatal metabolic complication. - Severe skin reactions including Stevens‑Johnson syndrome. - Hepatotoxicity signs such as jaundice. - Persistent vomiting leading to dehydration.

Before prescribing Glucophage Sr, clinicians consider several precautionary factors to minimize risks.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Evaluate hepatic function because liver disease can increase lactic acidosis risk. - Review history of alcohol abuse, which may predispose to metabolic acidosis. - Use caution in patients over 80 years of age or with low body weight. - Discontinue before any radiographic studies using iodinated contrast agents. - Monitor vitamin B12 levels during long‑term therapy.

Metformin can interact with a range of medicines, affecting its efficacy or safety profile.

Avoid: - Iodinated contrast media used for imaging studies. - Cimetidine, which may increase metformin plasma concentrations. - Certain antiretroviral drugs (e.g., didanosine) that raise the risk of lactic acidosis.

Use with caution: - Diuretics that may affect renal function. - ACE inhibitors or ARBs that can alter kidney perfusion. - Beta‑blockers that may mask hypoglycemia symptoms.